Starker Ausbruch !!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!! - 500 Beiträge pro Seite

[kafutznik]

1,84

[kafutznik]

Und ein wahsinns Volumen

[kafutznik]

Und weiter gehts wahnsinn

[kafutznik]

1,93

[kafutznik]

Starkes Volumen Vorbörslich 1,99

[kafutznik]

2,01 Ausbruch

[kafutznik]

2,04

[kafutznik]

2,14

[Schwarzermilan]

Hast Du zufällig von irgendwelchen News gehört kafutznik?

[kafutznik]

nein das ist ja das komische die kaufen wie irre in amiland auf höchstem nivoe alles aus dem ask und schon 10% der gesamten aktien wahnsinn

[Schwarzermilan]

Wir sind alleine merkst Du das......keiner hat es bisher bemerkt.....naja vielleicht kommt heute nachbörslich etwas besonderes!Schauen wir mal.

[Money4Life]

HAMMER!!!

strong buy....

http://www.stockhouse.com/news/news.asp?newsid=2944511&tick=…

http://www.stockhouse.com/news/news.asp?newsid=2944486&tick=…

[kafutznik]

Ja schauen wir mal muß jetzt weg aber ist schon wahnsinn wir werden sehen was passiert werde gegen später mal schauen aber schon sehr verdächtig der anstieg und das Volumen

[kafutznik]

Hammer News das gibt kein halten mehr wahnsinn

[Money4Life]

das schießt ja mächtig in die höhe

NVAX 11:24am 2.0401 - +0.3301 +19.30% N/A N/A 2.04 2.06

[Money4Life]

NVAX 11:25am 2.05 +0.34 +19.88% N/A N/A 2.04 2.05

und jetzt gehts erst los... hab nochmal nachgelegt...

[kafutznik]

Nachbörslich nochmal 225000 gehandelt zu 2,23 wahnsinn hat irgendwas mit Vogelgrippe zu tun war im Fernsehen auch was drüber in Amerika mit Präsident Busch der will das stark fördern und nvax hat wohl gute karten schaun wir mal aber das war ein wahnsinns Volumen gestern 28% der Aktien gehandelt

Melde mich später wieder werde erstmal nach weiteren Neuigkeiten schauen

[kafutznik]

Weiter gehts Vorbörslich 2,27

[AidanQ.]

...habe diesen wert auch getrade vor einigen wochen von 1,15 auf 2,20, damals ging es auch um vogelgrippe. allerdings ging es danach wieder runter bis auf 1,20.
in deutschland ist er ziemlich unbekannt, daher auch das geringe volumen. besser ist es in den usa zu kaufen.

viel glück,
allen investierten

[kafutznik]

http://www.stockhouse.ca/news/news.asp?newsid=2945992&tick=N…

[kafutznik]

2,23

[esenata]

Merkt Ihr Beiden ?? nicht, das Ihr alleine seid??
Oder hat jemand von Euch Beiden schon mal einen Hinweis gegeben, über welche Aktie Ihr da redet??
Oder seid Ihr Psychater?

[Schwarzermilan]

Es wird über Novavax geredet.

[kafutznik]

Natürlich Novavax Vorbörslich wird wieder gehandelt 2,20

[kafutznik]

2,26

[kafutznik]

2,34

[kafutznik]

2,53

[Schwarzermilan]

Schöner Verlauf für unser Baby *gg*

[mikel_ann]

... nein ganz alleine nicht.

Nur mit einem neuen Thread und einer wenig
aussagekräftigen Überschrift ist das nicht so einfach
zu erkennen worum es geht.

Aber bei Novavax ist schon seit ein paar Tagen leben.

[mikel_ann]

Day`s Range: 2.15 - 2.73
52wk Range: 0.70 - 4.10

[Schwarzermilan]

Stimmt man sieht es nicht auf anhieb das über nvax geredet wird.Ich gehe immer nur über die Aktien in den Thread, deshalb viel es mir garnicht so auf.

[mikel_ann]

Und hier noch mal eine der enigen sinnigen Meinungen aus dem Amiboard:



Speculation: "Investing in a way that carries a high degree of risk. An investor would hope to "score big" by investing in a speculative investment."

What means "speculating" with regards to going long NVAX?

Risks:
=====

- NVAX burn rate is around $2M a month so NVAX may have to do financing from time to time on terms that possibly won`t be favorable to the shareholders

- NVAX vaccine technology may be overlooked in the world where governments and interests of big corporations dictate the rules.

- NVAX vaccine may have a tough rime reaching the market due to the above or for any another reason, considering that it`s still in early stages of development (i.e. it may have unexpected side effects, it may face a stiff competition with another drug at the time it reaches the market etc.)

Rewards:
=======

- Due to the unique properties of NVAX vaccine technology (egg-free, could be produced faster then conventional vaccines, potentialy protect against different strains) it may become a "magic bullet" in the fight against highly mutable avian flu virus

- Due to the great urgency to develop and stockpile (each and every year) a working vaccine NVAX may get a fast track with the FDA

- Due to the "public health threat" status of avian flu, NVAX may start producing the vaccine much earler and without undergoing the same lengthy testing process to reach the market as other types of drugs

- NVAX vaccine program is currently supported by NIH and could possibly receive another sizeable grant, which would alleviate risks of money crunch

- recent developments in the world show that time-to-market for avian flu vaccine becomes a critical point. If there will be enough incentive from the government for vaccine developepment/production it may trigger biotechs with big pockets to
a) start their own flu vaccine development or, most likely, lincence already advanced technologies like NVAX`s on very favorable terms,
b) buy out the companies like NVAX to boost their portfolios and immediately gain a competitive edge in the viral drugs market.

TA: http://tinyurl.com/d6bxg

Disclaimer: the above is just my patologic opinion - take it with a flu shot...

Ich denke da haben viele nach dem letzten Hype nicht mit gerechnet.

[cyberhai]

Hier der Chart:



Gruß Cyberhai

[kafutznik]

RT 2,64 Novavax Wahsinn

[kafutznik]

Wave Biotech Announces Strategic Alliance on Pandemic Influenza Vaccine Production Technologies
10/17/2005

SOMERSET, N.J., Oct 17, 2005 /PRNewswire via COMTEX/ --
Wave Biotech, LLC, has announced today that the company is working with a number of worldwide pharmaceutical and biotech manufacturers that are making vaccines in the disposable Wave Bioreactor(R). In its latest collaboration effort, Wave Biotech has entered into an agreement with Novavax, Inc. (Nasdaq: NVAX), based in Malvern, PA, and both companies will jointly collaborate on the development of a commercial scale production process for Novavax`s pandemic influenza virus (avian flu) vaccine and other biological products. Wave Biotech will provide process and equipment expertise for the propriety technology based on disposable equipment for the manufacture of biologicals. The initial focus of the collaboration will be on Novavax`s H5N1 avian-flu-Like Particle (VLP) vaccine. The joint collaboration will demonstrate in a production process that can express potent vaccine at high yield at the 500-liter scale.

Vijay Singh, President and founder of Wave Biotech, LLC, issued the following statement: "Wave Biotech`s disposable cell culture technology is an ideal fit for the Novavax application because it provides scalable technology that can be delivered, installed, and commissioned quickly for possible worldwide use."

Non Traditional Approach May Prove Necessary in the Race Against Time

Wave Biotech first began development on their innovative technology for the bioreactor six years ago, which may prove to be a critical component in the race to develop vaccines before a flu pandemic has an opportunity to occur. The company offers a quick way to rapidly manufacture and deploy bioreactors of up to 500 liters operating volume. Using large plastic bags as cell culture vessels, the bags are inflated, filled with culture nutrients, and inoculated with the cells of choice. These bags are placed on special machines that rock in a back and forth motion, generating waves that effectively aerate and mix the contents, thus producing a highly effective environment for cell growth and productivity. The machines have been fully operational since 1999, and are currently in use at almost every pharmaceutical or biotech company worldwide. They have been licensed as part of processes to produce human therapeutics and are built to comply with all applicable FDA guidelines. Most critically, they have a proven track record with many cell lines and viruses having been used for the production of proteins, viruses, gene therapy products, and vaccines. Due to the inexpensive and simple pre-sterilized disposable culture bag, cell culture can be carried out by low-tech labor without the need for extensive plant infrastructure. The rocking machines are mass-produced and can be delivered in weeks as compared to six months or longer for traditional stirred tank bioreactors.

Dr. Singh acknowledged that current issues concerning the possibility of an influenza pandemic striking humanity in the very near future is based on several notable factors. "First of all, the influenza virus is capable of mutating rapidly so that most people would have no significant resistance and would succumb. Additionally there is a disturbing increase in the occurrence of avian flu in Asia as well as the latest evidence in some of the eastern European countries. It is clear that the great influenza epidemic of 1918 was avian origin, followed by others in 1957 and 1968," he said. "Statistically," he continued, "another appears to be due at this time." He also noted that there are now anti-viral pharmaceuticals that may be useful in treating those people infected by the influenza virus, but he cautioned that the efficacy and availability of such drugs are very limited.

"The problem with influenza vaccines is that the virus mutates rapidly and a vaccine made against one strain will likely be useless against another one," said Singh. "Making such a vaccine is very time consuming and takes eight to ten months to build up a significant stockpile of doses."

The manufacturing equipment developed by Wave Biotech can be quickly configured and deployed anywhere in the world within days. The cells only contact a single-use bag and these bags can be stockpiled for up to three years providing an option for almost instant vaccine manufacturing. The equipment has been optimized over several years to enable easy operation with minimal training required. This method would enable vaccine facilities to be rapidly established anywhere in the world to combat the disease at the local level, thus preventing its release into the general population. The disposable cell culture bags can be manufactured in large quantities in simple factories using heat seaming equipment, delivered pre-sterilized by radiation and ready for use.

Engineered Baculovirus

Current vaccine manufacturers use 1950`s chicken egg technology and other methods to make the vaccine. Singh considers these methods far more primitive because "even 350 million chicken eggs would only yield 300 million doses which would take at least six months to develop." Dr. Singh added, "This technology is not likely to save a significant number of people since compounding the problem is that if, indeed, the flu is avian origin, then where are the significantly large numbers of eggs needed to make the vaccine going to originate? The Spanish Flu epidemic of 1918 is estimated to have killed between 50 and 100 million people, at a time when world population was only 1.8 billion. Today we have 6.5 billion people and the impact of a virus such as the one in 1918 would clearly prove to be even more devastating."

Singh claims it is both necessary and critical for governments worldwide to secure alternative technologies to rapidly make an engineered cell line for vaccine production.

"One approach, developed by Novavax, is to identify the gene sequences of the virus as it exists now in the Far East and rapidly clone into baculovirus," said Dr. Singh. "This engineered baculovirus can be used to infect insect cells grown in liquid culture media and rapidly express large amounts of a suitable vaccine. This approach has been tested, proven and requires simple culture media that can be made from common chemicals. This way, it is possible to clone and develop a cell expressions system against a specific influenza strain within six weeks of securing the sample. While getting a cell line that produces the desired vaccine is only part of the story, in order to make sufficient quantities of the vaccine in such a time- sensitive manner, it will be essential to grow large numbers of cells using thousands of liters of cell culture capability."

About Wave Biotech

Wave Biotech is a research-based company that develops and manufactures innovative process equipment for the pharmaceutical and biotechnology industries. The Company`s focus is on developing disposable bioprocess equipment for the operation traditionally requiring stainless-steel tanks and piping. Key products, such as the Wave Bioreactor(R), WaveMixer(R), FlexMixer(R), and Sterile Tube Fuser, feature disposable contact materials that eliminate cleaning and validation, thereby reducing costs in operations ranging from cell culture, media preparation, and buffer dissolution and thawing process intermediates to patient specific cell therapy in hospitals. These unique, patented, devices can be installed and commissioned rapidly, thereby drastically reducing the time-to-market for biological products. Wave Biotech`s equipment is in use with hundreds of companies worldwide, both for R&D, as well as commercial applications.

SOURCE Wave Biotech, LLC


Was für eine Meldung gestern bei Tageshoch geschlossen 3,27 Novavax wer jetzt nicht Einsteigt dem ist nicht zu helfen nur meine Meihnung

[2Tuvok]

Bin mal gespannt ab wann
der US Handel beginnt.

[buxte]

Habe mir auch welche ins Depot gelegt

[Sam1976]

Hie hat einer von euch den RT-Link von NOVAVAX?

[chri999s]

http://de.finance.yahoo.com/q/ecn?s=NVAX

[Sam1976]

[posting]18.328.887 von chri999s am 18.10.05 15:09:20[/posting]Danke dir

[holgigli]

[posting]18.213.627 von kafutznik am 10.10.05 16:17:51[/posting]noch besser ist:
http://www.island.com
und dann NVAX unter "BookViewer" live anschauen

holgi

[bulle45]

4,4 USD Hoch in Frankfurt 3,65 EUR

[bulle45]

4,00 USD ca 20.000.000 Stck

[AidanQ.]

...und das gute: intraday konsolidierung, das erspart uns einiges an korrekturen

[2Tuvok]

Ein Sch...wetter,es ist am Pissen,
der Hund will raus...,aber der Kurs

[cyberhai]

Flu-resistant investments? Try vaccines, gold
Mon Oct 24, 2005 02:36 PM ET
By Bill Berkrot

NEW YORK, Oct 24 (Reuters) - A global bird flu pandemic, or even widespread fear of such a breakout, would be a devastating blow to numerous industries and the world economy, but there may be ways to make investment portfolios at least partly flu resistant.

The disease, which has killed more than 60 people in Asia since 2003, prompting the destruction of hundreds of thousands of ducks and chickens, has been detected in birds in several European countries, fanning fears of a mounting health crisis.

No one knows how many people would die in an H5N1 avian flu pandemic should the virus mutate into one that can spread from human to human, but the World Health Organization says the toll could be in the millions or tens of millions, depending on how virulent the virus turns out to be.

"People are not going to be congregating where other people are. So I would think that eBay Inc. (EBAY.O: Quote, Profile, Research) and companies that sell on-line would probably do very well because people just aren`t going to go to the mall to do shopping," said Jim Huguet, president and co-CEO of Great Companies LLC.

Huguet also suggested companies that make home entertainment equipment and video games could benefit from a stay-at-home mentality.

"It sounds gruesome but I guess you could invest in the funeral services companies. Obviously they would see a significant increase in business," added Huguet, mentioning Stewart Enterprises (STEI.O: Quote, Profile, Research) and Service Corp International (SCI.N: Quote, Profile, Research) .

Most analysts believe it premature to start making defensive moves based on a health crisis that might not materialize. But given the frightening avian flu forecasts from the Word Health Organization it`s not too soon to start thinking about it.

"It`s too early to be avoiding the transportation area and even too early to be avoiding large food groups," Gregory Spear, editor of Spear`s Security Industry Analyst, said of industries that could be hit hard by a flu panic.

But recent editions of the newsletter focusing on homeland security stocks discussed companies such as specialty drug maker Novavax Inc. (NVAX.O: Quote, Profile, Research) and Crucell NV (CRCL.AS: Quote, Profile, Research) (CRXL.O: Quote, Profile, Research) , a company that owns patents on a way to make commercial quantities of vaccines without injecting chicken eggs.

Makers of vaccines and anti-viral drugs, such as Roche Holding (ROG.VX: Quote, Profile, Research) and Sanofi-Aventis (SASY.PA: Quote, Profile, Research) would be an obvious choice for stocks that could flourish in the midst of a flu epidemic, several analysts said.

If flu vaccines are to be produced the conventional way, a potential beneficiary could be egg producers, such as Cal-Maine Foods (CALM.O: Quote, Profile, Research) , noted Steve Brozak, president of WBB Securities.

Brozak, who made an unsuccessful bid for U.S. Congress from New Jersey in 2004, has been pushing for a government-led Manhattan Project type meeting of the top minds in drug discovery to deal with a potential pandemic.

Al Goldman, chief market strategist at A.G. Edwards, believes major pharmaceutical stocks could be a good defensive investment despite their recent woes and bad publicity.

"I think it is a group that will start attracting money with the world now scared to death about avian flu and other illnesses," Goldman said. "Consumer sentiment is poor but you`re going to buy your pharmaceuticals no matter what."

Thomas Lydon, president of Global Trends Investments, suggests charting investments against the S&P 500 200-day average and not allow them to get below a certain point.

"It`s a gradual way to protect your downside," he said. "And emotionally, which is a big part of investing, people are able to grasp it because you`re able to look at the chart."

But should a genuine flu panic break out, Lydon said, "hard currency or precious metals are the safe areas. In protecting yourself, maybe gold makes sense."

That sentiment was echoed by Peter Schiff, President of Euro Pacific Capital, especially if Asia is the epicenter of a flu crisis as predicted.

"Asia is where everything is getting produced. If Asia was less productive they`d ask for their money back from the United States and the result could be a selling-off of the dollar," Schiff said.

"Gold should do well. If the dollar goes down, gold goes up automatically," Schiff added.

Should the worst case scenario pan out and a survivalist bunker mentality take hold, suggested Brozak, with tongue in cheek, "the best bets may be canned goods and shotgun shells." (additional reporting by Jennifer Coogan and Cal Mankowski)

[bulle45]

SK 4,1501 USD 13.700 Stck ca 25 mill Stck Umsatz

[Bullenjaeger]

Novavax to Present at the C.E. Unterberg, Towbin Life Sciences Conference
10/24/2005

MALVERN, Pa., Oct 24, 2005 /PRNewswire-FirstCall via COMTEX/ --
Novavax, Inc. (Nasdaq: NVAX) a specialty biopharmaceutical company, today announced that Dr. Rahul Singhvi, President and Chief Executive Officer, will be presenting at the C.E. Unterberg, Towbin Life Sciences Conference on Wednesday, October 26, 2005.

WHEN: Wednesday, October 26, 2005 11:00 a.m. EDT

WHERE: The Palace Hotel, 455 Madison Avenue, New York, NY 10022

HOW: The live broadcast of the presentation can be accessed through
our website at http://www.novavax.com. After the presentation date, the
web cast will be archived on our website for 90 days.

Dr. Rahul Singhvi

Dr. Singhvi was appointed President and CEO of Novavax in August, 2005. He joined the Company in April, 2004 as Vice President, Pharmaceutical Development and Manufacturing Operations. Dr. Singhvi joined Novavax after 10 years` experience with Merck & Co., where he most recently served as a Director within the Merck Manufacturing division. Dr. Singhvi holds both a Master and Doctorate of Science degree in Chemical Engineering from MIT, a Master of Business Administration from The Wharton School, and a Bachelor of Technology from IIT, Kanpur, India. He holds several patents in the area of cell culturing systems and has co-authored numerous publications and abstracts on biochemical engineering and cell physiology.

About Novavax, Inc.

Novavax, Inc. is a product development company focused on the research, development and commercialization of products utilizing its proprietary drug delivery and biological technologies for large and growing markets. Novavax`s drug delivery technologies include the Micellar Nanoparticle (MNP) technology which is the basis for the development of its first FDA approved product, ESTRASORB. In addition to MNP, Novavax drug delivery technologies include Novasomes (paucillamellar non-phospholipid liposomes) and Sterisome (subcutaneous depot delivery) technologies. Novavax`s vaccine technologies include virus like particle manufacturing technology utilizing the baculovirus expression system in insect cells as well as novel vaccine adjuvants based on novasomes and dendrimer technologies.

Statements made in this press release that state Novavax`s or management`s intentions, hopes, beliefs, expectations, or predictions of the future are forward-looking statements. Forward-looking statements include but are not limited to statements regarding usage of cash, product sales, future product development and related clinical trials and future research and development, including FDA approval. Novavax`s actual results could differ materially from those expressed in such forward-looking statements. Such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company, or industry results, to be materially different from those expressed or implied by such forward-looking statements. Such factors include, among other things, the following: general economic and business conditions; ability to enter into future collaborations with industry partners, including an ESTRASORB(R) licensing agreement; competition; unexpected changes in technologies and technological advances; ability to obtain rights to technology; ability to obtain and enforce patents; ability to commercialize and manufacture products; ability to establish and maintain commercial-scale manufacturing capabilities; results of clinical studies; progress of research and development activities; business abilities and judgment of personnel; availability of qualified personnel; changes in, or failure to comply with, governmental regulations; the ability to obtain adequate financing in the future through product licensing, co-promotional arrangements, public or private equity financing or otherwise; and other factors referenced herein. Additional information is contained in Novavax`s annual report on Form 10K for the year ended December 31, 2004 and quarterly reports on Form 10Q for the quarters ended March 31, 2005 and June 30, 2005, incorporated herein by reference. Statements made herein should be read in conjunction with Novavax`s annual and quarterly reports filed with the SEC. Copies of these filings may be obtained by contacting Novavax at 508 Lapp Road, Malvern, PA 19355 Tel [phone] or the SEC at http://www.sec.gov.

SOURCE Novavax, Inc.

Investor Relations: Kathy Hamilton, Novavax, Inc., [phone], Email: [e-mail] http://www.prnewswire.com

Copyright (C) 2005 PR Newswire. All rights reserved. ********************************************************************** As of Thursday, 10-20-2005 23:59, the latest Comtex SmarTrend(SM) Alert, an automated pattern recognition system, indicated an UPTREND on 08-25-2005 for NVAX @ $1.29. (C) 2005 Comtex News Network, Inc. All rights reserved.

[AidanQ.]

...bin mal gespannt, wie es heute weitergeht. ist schon fast unheimlich, dieser kursanstieg. gestern intradaykorrektur, die dürfte uns größer downs ersparen.

[kafutznik]

Das ist erst der Anfang

[kafutznik]

6,01

[elbono]

Allen investierten herzlichen Glückwunsch! Ist schon erstaunlich was Euer Papier hier hinlegt.

neidischguck